Author

Chong Qin

Marine Biomedical Research Institute of QingdaoORCID 0000-0001-8108-1698Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioinformatics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Dan TengiD· 2 shared Mingyue ZhengiD· 2 shared Sulin ZhangiD· 2 shared Xiao WangiD· 2 shared Dan Wang· 1 shared Guizhen Zhou· 1 shared J Q XuiD· 1 shared Kaixian CheniD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Dan TengORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioinformaticsbioRxivPreprintAug 17, 2026

MG2Act: A Mechanism-Inspired Sequential Attention Framework for Molecular Glue Degradation Prediction

Zhiyao Zhuang, Dan Teng, Xiaojing Xu…·Chong Qin

MG2Act predicts molecular glue degradation by modeling sequential interactions between E3 ligase and substrate, outperforming baselines and identifying new degraders.

DOI 10.64898/2026.08.08.739980

deep learningdrug response / drug discovery

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 12, 2026

Functional orthogonality of WRN inhibitor resistance enables alternating therapy and mutation-tolerant inhibitor design in MSI-H cancers

Guizhen Zhou, Dan Teng, Dan Wang…·Mingyue Zheng

This study shows that resistance to different WRN inhibitors in MSI-H cancers creates orthogonal vulnerabilities, enabling alternating therapy and mutation-tolerant inhibitor design.

DOI 10.64898/2026.06.09.731233

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologyJournal of Medicinal ChemistryPeer-reviewedMay 2, 2025

PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer

Xiao-Lei Meng, Xiaolin Hu, Shan Gao…·Chong Qin

This study develops PSMA-guided PROTACs for prostate cancer, showing they selectively degrade target proteins in PSMA-overexpressing cells and improve therapeutic effects in vivo.

16 citationstop 5%

humanexperimental assay

𝕏 PostBluesky